Patients with metastatic breast cancer have a new FDA-approved treatment option. Federal regulators approved the drug, Verzenio, which blocks enzymes that promote the growth of cancer cells for women with HR-positive, HER2-negative breast cancer. This new drug is targeted specifically for survivors who have not responded to hormone therapy.
To read the complete article, click here.